

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO. 09/661,658	FILING DATE 09/14/2000	FIRST NAMED INVENTOR  Andrew D. Ellington	ATTORNEY DOCKET NO. 119927-1021	CONFIRMATION NO. 9207
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C. ONE FINANCIAL CENTER BOSTON, MA 02111			EXAMINER GIBBS, TERRA C	
			ART UNIT	PAPER NUMBER
			1635 DATE MAILED: 01/14/200	3 16

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/661,658	ELLINGTON ET AL.
Office Action Summary	Examiner	Art Unit
		with the correspondence address
The MAII ING DATE of this comm	Terra C. Gibbs nunication appears on the cover sheet	WILLI LITE COLLESPONDENCE ASS.
The MAILING DATE of this comme		MONTH(S) FROM
A QUARTEMED STATUTORY PERIOD	O FOR REPLY IS SET TO EXPIRE 1	word in the first the second
THE MAILING DATE OF TITIO CONTINUOUS THE MAILING DATE OF TITIO CONTINUOUS THE PROVIDE THE	sions of 37 CFR 1.136(a). In no event, nowever, may communication. irty (30) days, a reply within the statutory minimum of tum statutory period will apply and will expire SIX (6) Murroply will, by statute, cause the application to become onths after the mailing date of this communication, even	thirty (30) days will be considered timely.  MONTHS from the mailing date of this communication.
Status		
1) Responsive to communication(		
2a) This action is <b>FINAL</b> .	L for formal	matters, prosecution as to the merits is
closed in accordance with the	dition for allowance except for formal of practice under Ex parte Quayle, 1935	matters, prosecution as to the merits is 5 C.D. 11, 453 O.G. 213.
Disposition of Claims		
1 28 is/are pending in	n the application.	
4a) Of the above claim(s)	_ is/are withdrawn norm consider and m	
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		
is/are objected	to.	
ON Claim(a) 1-28 are subject to re	estriction and/or election requirement.	
8) Claim(s) <u>1-28</u> are subject to 10  Application Papers		
	by the Examiner.	
		o by the Examiner.
10) I ne drawing(s) med on	any objection to the drawing(s) be held in	abeyance. See 37 CFR 1.85(a).
— — — — and drawing correcti	ion filed on is. a) approve	<i>'</i> = ··
11) the proposed drawing correct	s are required in reply to this Office action.	١.
If approved corrected drawings	s are required in rophy to an	
12) The oath or declaration is obje	120	
Priority under 35 U.S.C. §§ 119 and 1	12U	'.S.C. § 119(a)-(d) or (f).
13) Acknowledgment is made of	a claim for foreign priority under 05 5	•
N□ N□ Some * c)□ No	one of:	
	ariarity documents have been receive	ed.
3 Copies of the certified	copies of the priority documents have	7 2(a))
application it in a	in the setting conti	sies not receiveu.
of c	a claim for domestic priority under our	5.0.2.5
14) I The translation of the fo	oreign language provisional application	n has been received.
15) Acknowledgment is made of	a claim for domestic pro-	
Attachment(s)	. 🗖 .	Literations Summary (PTO-413) Paper No(s)
1) Notice of References Cited (PTO-892)	g Review (PTO-948) 5) 🔲 1	Notice of Informal Patent Application (PTO-152) Other:
2) Notice of Draftsperson's Patent Drawing 3) Information Disclosure Statement(s) (PT		Part of Paper No. 15

Application/Control Number: 09/661,658

Art Unit: 1635

## DETAILED ACTION

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

Pursuant to 35 U.S.C. 121 and 37 C.F.R. 1.141, the sequences of claims 6-11 and 20-25 are restricted to **one** sequence. The Commissioner has partially waived the requirements of 37 C.F.R. 1.141 and will permit a reasonable number of such nucleotide sequences to be claimed in a single application. Under this policy, up to 10 of independent and distinct nucleotide sequences will be examined in a single application (see MPEP 803.04 and 2434).

Claims 6-11 and 20-25 specifically claim any one of SEQ ID NOs: 1, 2, 3, 4, 5, or 6, directed to aptazyme constructs comprising oligonucleotides of SEQ ID NOs: 1, 2, 3, 4, 5 or 6. The instant sequences are considered to be unrelated, since each sequence claimed is structurally and functionally independent and distinct for the following reasons: each sequence has a unique nucleotide sequence and each sequence is structurally distinct. Furthermore, a search of more than one (1) of the sequences claimed presents an undue burden on the Patent and Trademark Office due to the complex nature of the search and corresponding examination of more than one (1) of the claimed sequences. Further, because a separate search would be required for each one of the sequences of claims 6-11 and 20-25, restriction for examination purposes as indicated is proper. In view of the foregoing, one (1) sequence is considered to be a reasonable number of sequences for examination. Accordingly, applicants are required to elect one (1) sequence from SEQ ID NOs: 1-6 of claims 6-11 and 20-25.

This is not a species requirement, but a restriction of distinct and independent inventions: unique and structurally distinct nucleotide sequences. Applicant is required to elect one SEQ ID

Application/Control Number: 09/661,658

Art Unit: 1635

NO. as recited in claims 6-11 and 20-25. Currently claims 1-5, 12-19 and 26-29 are generic and

will be examined as they read on the elected subject matter.

Applicant is advised that the reply to this requirement to be complete must include an

election of the invention to be examined even though the requirement be traversed (37

CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

currently named inventors is no longer an inventor of at least one claim remaining in the

application. Any amendment of inventorship must be accompanied by a petition under 37

CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Terra C. Gibbs whose telephone number is (703) 306-3221. If

attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John L.

LeGuyader can be reached on (703) 308-0447. The fax phone numbers for the organization

where this application or proceeding is assigned are (703) 746-8693 for regular communications

and (703) 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is (703) 308-0196.

tcg

January 10, 2003

SUPERVISORY PATFACT CYAPINER

TECHAIO:

:0

SUPERVISORY PATENT EXAMINER

Page 3

YECHNOLOGY CENTER 1600